Abstract
Ebola and Marburg viruses, family Filoviridae, are among the best known examples of emerging and re-emerging pathogens. Although outbreaks have been sporadic and geographically restricted to areas of Central Africa, the hemorrhagic fevers caused by these viruses are remarkably severe and are associated with high case fatality rates often exceeding 80 percent. In addition to humans, these viruses have decimated populations of wild apes in Central Africa. Currently, there are no vaccines or effective therapies available for human use. Progress in understanding the geneses of the pathophysiological changes that make filoviral infections of humans so destructive has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the molecular mechanisms of filoviral pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. In addition, substantial progress has been made in developing recombinant vaccines against these viruses.
Keywords: filoviral particles, furin-like endoprotease, ICAM, TNF-related apoptosis-inducing ligand (TRAIL), coagulation defects, proinflammatory
Current Molecular Medicine
Title: Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures
Volume: 5 Issue: 8
Author(s): Lisa E. Hensley, Steven M. Jones, Heinz Feldmann, Peter B. Jahrling and Thomas W. Geisbert
Affiliation:
Keywords: filoviral particles, furin-like endoprotease, ICAM, TNF-related apoptosis-inducing ligand (TRAIL), coagulation defects, proinflammatory
Abstract: Ebola and Marburg viruses, family Filoviridae, are among the best known examples of emerging and re-emerging pathogens. Although outbreaks have been sporadic and geographically restricted to areas of Central Africa, the hemorrhagic fevers caused by these viruses are remarkably severe and are associated with high case fatality rates often exceeding 80 percent. In addition to humans, these viruses have decimated populations of wild apes in Central Africa. Currently, there are no vaccines or effective therapies available for human use. Progress in understanding the geneses of the pathophysiological changes that make filoviral infections of humans so destructive has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the molecular mechanisms of filoviral pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. In addition, substantial progress has been made in developing recombinant vaccines against these viruses.
Export Options
About this article
Cite this article as:
Hensley E. Lisa, Jones M. Steven, Feldmann Heinz, Jahrling B. Peter and Geisbert W. Thomas, Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures, Current Molecular Medicine 2005; 5 (8) . https://dx.doi.org/10.2174/156652405774962344
DOI https://dx.doi.org/10.2174/156652405774962344 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cold-induced Anaphylaxis: The Case of a 9-year-old Child and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Immunotherapy of Melanoma
Current Molecular Pharmacology Decreasing Arterial Aging by Controlling Blood Pressure Levels and Hypertension: A Step Forward
Current Vascular Pharmacology Statin Therapy
Current Pharmaceutical Design Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Antagonists of the Vasopressin V1 Receptor and of the β<sub>1</sub>-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes-but the Mechanisms Differ
Current Neuropharmacology Fatal Disseminated Toxoplasmosis During Primary HIV Infection
Current HIV Research Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus
Current Drug Targets Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Long Acting Betaxolol Ocular Inserts based on Polymer Composite
Current Drug Delivery Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Current Vascular Pharmacology Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology Cardiotoxicity of 5-Fluorouracil
Cardiovascular & Hematological Agents in Medicinal Chemistry An Inducible Expression System for Recombinant Sca Proteins with an Autotransporter Domain from <i>Orientia Tsutsugamushi in Escherichia coli</i>
Protein & Peptide Letters